ROLKE JAMES (Chief Scientific Officer) received a stock award from LA JOLLA PHARMACEUTICAL CO
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 5/4/2020ACC: 0000920465-20-000065
Officer· Chief Scientific Officer
Since Aug 2018
+266.00
Net shares
Net buyer
$820.61
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
266.00 acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+133.00
Price / share
$6.17
Trade value
$820.61
% of position
0.2%
4/30/2020
81.29K→81.43K
Total
Net shares
+133.00
Net value
$820.61
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/30/2020 | A · Award | +133.00 | $6.17 | $820.61 | 0.2% | 81.29K | 81.43K |
| Total | +133.00 | $820.61 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
133.00 shares
Shares
+133.00
Strike price
7.26
Held after
133.00
Exercisable
—
4/30/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock133.00 shares | 4/30/2020 | A · Award | +133.00 | 7.26 | — | 133.00 |